Chronic Kidney Failure
Conditions
Interventions
Hemodiafiltration using ABH-22PA for 6 weeks
Sponsors
Wakimachi Kawashima Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have received hemodiafiltraion using ABH-P or ABH-PA for more than one month at the time of informed consent. 2)Qb 300 mL/min is possible. 3)Outpatients. 4)Ability to understand this research and to give written informed consent. 5)Aged 20 to <80 years at the time of informed consent.
Exclusion criteria
Exclusion criteria: 1)Need to blood purification other than hemodiafiltraion. 2)With a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP). 3)Patients who will participate in other clinical trial during this research. 4)Judged ineligible by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Reduction rate 2) Removal amount 3) Albumin leakage 4) Transmembrane pressure and Number of alarms 5) Antithrombotic property 6) Adverse events and Device deficiencies | — |
Countries
Japan
Contacts
Public ContactKenji Fujiwara
Wakimachi Kawashima Clinic Division of clinical engineering
Outcome results
None listed